- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Bile duct cancer (cholangiocarcinoma)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Futibatinib – March 2025
Futibatinib; Tablet 4 mg; Lytgobi®
Last updated
12 March 2025